Drug Trial Radar · NCT07219849
A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure
Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
164
Planned (sponsor's estimate)
Start
Oct 17, 2025
Primary completion
Apr 2026
Study completion Apr 2026
Sponsor
- Lead sponsor
- Alixer Nexgen Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.
Conditions
- Seasonal Allergic Rhinitis (SAR)
Interventions
ALDP001 Nasal SprayDrug
Experimental Arm
Placebo Nasal sprayDrug
Controlled arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Total Nasal Symptom ScoreTime frame: Day 9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliantha Research
Mississauga, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.